Biomarkers of low grade glioma and pediatric neuroblastoma

A method of alleviating or relieving a selected subject having pediatric neuroblastoma, comprising:

• obtaining a neuroblastoma tumor sample derived from a subject having pediatric neuroblastoma;
• quantifying an expression level of one or more biomarkers that are associated with overall survival in pediatric neuroblastoma in the neuroblastoma tumor sample derived from the subject and a noncancerous control from the subject, wherein the biomarker comprises one or more of MAPT, CASP3, and CASP9;
• identifying the selected subject as having a shorter overall survival if the expression level of one or more of the biomarkers MAPT, CASP3, and CASP9 is lower in the neuroblastoma tumor sample derived from the subject compared to a reference selected from the noncancerous control or expression level at the highest quintile (20%) of the biomarker levels of a reference population of pediatric neuroblastoma patient samples;
• and
• administering to the selected subject a therapeutically effective amount of an activator of MAPT, an activator of CASP3, an activator of CASP9, or a combination thereof.